
|Videos|March 31, 2022
A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma
Oncologists debate whether TKI monotherapy has a place in renal cell carcinoma treatment after the CLEAR trial.
Advertisement
Episodes in this series

Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
All-Oral Revumenib Regimen May Show Advantage in Newly Diagnosed AML
2
Talquetamab Combo Yields Responses in Multiple Myeloma With True EMD
3
Linvoseltamab Yields High Response in Newly Diagnosed Multiple Myeloma
4
MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC
5




























































































